These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33406304)

  • 1. Azacytidine induced localized Sweets syndrome in Myelodysplastic syndrome.
    Dev T; Dudani P; Bhari N
    Dermatol Ther; 2021 Mar; 34(2):e14754. PubMed ID: 33406304
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
    Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
    [No Abstract]   [Full Text] [Related]  

  • 3. Azacitidine-induced Sweet syndrome: Two unusual clinical presentations.
    Tiwari SM; Caccetta T; Kumarasinghe SP; Harvey N
    Australas J Dermatol; 2018 Aug; 59(3):e224-e225. PubMed ID: 29044459
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.
    Martinelli S; Rigolin GM; Leo G; Gafà R; Lista E; Cibien F; Sofritti O; Daghia G; Cavazzini F; Cuneo A
    Int J Hematol; 2014; 99(5):663-7. PubMed ID: 24554168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 7. Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.
    Lin CH; Yeh SP; Lin TY
    Ann Hematol; 2015 Nov; 94(11):1925-6. PubMed ID: 26233682
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
    D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
    Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
    Jennane S; El Haddad M; Mahtat EM; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2017 Dec; 75(6):713-714. PubMed ID: 29043987
    [No Abstract]   [Full Text] [Related]  

  • 10. Azacitidine-associated Sweet's syndrome.
    Trickett HB; Cumpston A; Craig M
    Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
    Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I
    Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231
    [No Abstract]   [Full Text] [Related]  

  • 12. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 13. Azacitidine: a new medication associated with Sweet syndrome.
    Tintle S; Patel V; Ruskin A; Halasz C
    J Am Acad Dermatol; 2011 May; 64(5):e77-9. PubMed ID: 21496689
    [No Abstract]   [Full Text] [Related]  

  • 14. Rare lobular capillary hemangioma associated with azacitidine in high-risk myelodysplastic syndrome patient.
    Grafanaki K; Kourakli A; Skeparnias I; Spiliopoulos T; Koumoundourou D; Bravou V; Alexopoulos A; Symeonidis A; Georgiou S
    Dermatol Ther; 2021 Mar; 34(2):e14884. PubMed ID: 33594760
    [No Abstract]   [Full Text] [Related]  

  • 15. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
    Lamarque M; Raynaud S; Itzykson R; Thepot S; Quesnel B; Dreyfus F; Rauzy OB; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Visanica S; Stamatoullas A; Fenaux P; Adès L
    Blood; 2012 Dec; 120(25):5084-5. PubMed ID: 23243156
    [No Abstract]   [Full Text] [Related]  

  • 16. WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.
    Falconi G; Fabiani E; Ottone T; Piciocchi A; Lavorgna S; Criscuolo M; Fianchi L; Gurnari C; Postorino M; Picardi A; Palmieri R; Lo-Coco F; Voso MT
    Leuk Lymphoma; 2020 Apr; 61(4):979-982. PubMed ID: 31797711
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
    Kantarjian HM
    J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitine (vidaza) for myelodysplastic syndrome.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

  • 20. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
    Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
    Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.